CG Oncology, Inc. (CGON) Stock Statistics & Valuation Metrics

CG Oncology, Inc. has a market cap or net worth of $3.15B. The enterprise value is $2.42B.

CG Oncology, Inc. has 80,666,176 shares outstanding. The number of shares has decreased by -2.65% in one year.

CG Oncology, Inc.’s return on equity (ROE) is -0.12 and return on invested capital (ROIC) is -15.63%.

The current PE Ratio of CG Oncology, Inc. is ―. CG Oncology, Inc.’s PEG ratio is -0.53.

In the last 12 months, CG Oncology, Inc. had revenue of 1.14M and earned -88.04M in profits. Earnings per share was -1.41.

In the last 12 months, operating cash flow was -116.79M and capital expenditures -336.00K, giving a free cash flow of -117.13M billion.

CG Oncology, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

CG Oncology, Inc. upcoming earnings date is Mar 27, 2026, Before Open (Confirmed).

CG Oncology, Inc. as a current ratio of 35.30, with Debt / Equity ratio of 1.05%

In the past 12 months, CG Oncology, Inc. has paid 0.00 in taxes.

CG Oncology, Inc. EV to EBITDA ratio is -13.40, with an EV/FCF ratio of -19.45.

CG Oncology, Inc. has $680.26M in cash and marketable securities with $7.24M in debt, giving a net cash position of $673.02M billion.

Gross margin is 20.29%, with operating margin of -10067.25%, and net profit margin of -7729.50%.

The average price target for CG Oncology, Inc. is $69.64, which is 11.43% higher than the current price. The consensus rating is Strong Buy